42 related articles for article (PubMed ID: 38681733)
1. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
2. Distribution of
Abudukeremu M; Ayoufu A; Tuerhong A; Paizula X; Ou JH
Open Life Sci; 2024; 19(1):20220728. PubMed ID: 38681733
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.
Wang T; Zhao T; Bao S; Jia L; Feng J; Yu A; Sun L; Guo X; Li H; Yu L
Medicine (Baltimore); 2020 Jul; 99(29):e20582. PubMed ID: 32702814
[TBL] [Abstract][Full Text] [Related]
4. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
5. [CYP2D6 genotypes and phenotypes in Chinese Han, Uygur and Kazakh populations].
Li GC; Yang J; Zhou T; Chen ZG; Chen W
Yao Xue Xue Bao; 2011 Feb; 46(2):238-42. PubMed ID: 21542297
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
7. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Ma L; Yuan Y; Li J; Yu C; Zhao J
Int J Immunogenet; 2020 Dec; 47(6):539-545. PubMed ID: 32862511
[TBL] [Abstract][Full Text] [Related]
8. Germline and somatic genetic variability of oxysterol-related genes in breast cancer patients with early disease of the luminal subtype.
Holý P; Hlaváč V; Ostašov P; Brynychová V; Koževnikovová R; Trnková M; Kopečková K; Měšťáková S; Mrhalová M; Souček P
Biochimie; 2022 Aug; 199():158-169. PubMed ID: 35525372
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones.
Niwa T; Yasuda S; Yamamoto Y; Murakami M; Ishii R
Pharmazie; 2021 Dec; 76(12):611-613. PubMed ID: 34986958
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative activity of Tamoxifen, Vitamin D3 and their concomitant treatment.
Yetkin D; Balli E; Ayaz F
EXCLI J; 2021; 20():1394-1406. PubMed ID: 34737683
[TBL] [Abstract][Full Text] [Related]
11. Toward predicting CYP2D6-mediated variable drug response from
van der Lee M; Allard WG; Vossen RHAM; Baak-Pablo RF; Menafra R; Deiman BALM; Deenen MJ; Neven P; Johansson I; Gastaldello S; Ingelman-Sundberg M; Guchelaar HJ; Swen JJ; Anvar SY
Sci Transl Med; 2021 Jul; 13(603):. PubMed ID: 34290055
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
He W; Eriksson M; Eliasson E; Grassmann F; Bäcklund M; Gabrielson M; Hammarström M; Margolin S; Thorén L; Wengström Y; Borgquist S; Hall P; Czene K
Ann Oncol; 2021 Oct; 32(10):1286-1293. PubMed ID: 34284099
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Sanchez-Spitman AB; Swen JJ; Dezentjé VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Sci Rep; 2021 Jan; 11(1):415. PubMed ID: 33432065
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
Bae JW; Oh KY; Yoon SJ; Shin HB; Jung EH; Cho CK; Lim CW; Kang P; Choi CI; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
